Home Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
 

Keywords :   


Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone

2015-04-14 19:30:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. & AMES, Iowa rVSV-ZEBOV-GP (V920) Now Being Studied in Three Key Safety and Efficacy Clinical Trials KENILWORTH, N.J. & AMES, Iowa--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine candidate was originally developed by the Public Health Agency of Canadas National Microbiology Laboratory and licensed to NewLink Genetics in 2010. On Nov. Language: English Contact: Merck Media:Pam Eisele, 267-305-3558orImraan Munshi, 215-652-0059Investor:NewLink Genetics:Jack Henneman, 515-598-2561orMerck:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NLNK Exchange: NASDAQ read more

Tags: iii trial phase sierra

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
04.11Tropical Depression Eighteen Graphics
04.11Tropical Depression Eighteen Public Advisory Number 4A
04.11Remnants of Patty Graphics
04.11Atlantic Tropical Weather Outlook
04.11Eastern North Pacific Tropical Weather Outlook
04.11Paper Excellence Group Rebrands as Domtar
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
More »